Peer-reviewed research by Nexcyon.
PUBLICATIONS
Freise KJ, Reinemeyer C, Warren K, Lin TL, Clark TP. Single‐dose pharmacokinetics and bioavailability of a novel extended duration transdermal buprenorphine solution in cats. J. vet. Pharmacol. Therap., 45, S31-S39, 2022. (link to article)
Clark TP, Linton DD, Freise KJ, Lin TL. Multicentered masked placebo‐controlled phase 2 clinical study of an extended duration transdermal buprenorphine solution for postoperative pain in cats. J. vet. Pharmacol. Therap., 45, S40-S51, 2022. (link to article)
Clark TP, Linton DD, Freise KJ, Lin TL. Multicentered masked placebo‐controlled phase 3 clinical study of an extended duration transdermal buprenorphine solution for post‐operative pain in cats. J. vet. Pharmacol. Therap., 45, S52-S66, 2022. (link to article)
Clark TP, Linton DD, Freise KJ, Reinemeyer C, Newkirk KM, Aulbach A, Lin TL. Margin of safety of extended‐duration transdermal buprenorphine solution following multiple‐dose administrations to cats. J. vet. Pharmacol. Therap., 45, S67-S84, 2022. (link to article)
Clark TP. The history and pharmacology of buprenorphine: New advances in cats. J. vet. Pharmacol. Therap., 45, S1-S30, 2022. (link to article)
Martinez SA, Wilson MG, Linton DD, Newbound GC, Freise KJ, Lin T-L, Clark TP. The safety and effectiveness of a long-acting transdermal fentanyl solution compared to oxymorphone for the control of postoperative pain in dogs: a randomized, multicenter clinical study. J. vet. Pharmacol. Therap., 37(4):394-405, 2014. (link to article)
Freise KJ, Lin T-L, Fan TM, Recta V, Clark TP. Evidence based medicine: the design and interpretation of non-inferiority clinical trials in veterinary medicine. J Vet Intern Med 27(6):1305-07, 2013. (link to article)
KuKanich B and Clark TP. The history and pharmacology of fentanyl: relevance to a novel, long-acting transdermal fentanyl solution newly approved for use in dogs. J. vet. Pharmacol. Therap. 35 (Suppl. 2), 3–19, 2012. (link to article)
Freise KJ, Savides MC, Riggs KL, Owens JG, Newbound GC, Clark TP. Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. J. vet. Pharmacol. Therap. 35 (Suppl. 2), 21–26, 2012. (link to article)
Freise KJ, Newbound G C, Tudan C, Clark TP. Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. J. vet. Pharmacol. Therap. 35 (Suppl. 2), 27–33, 2012. (link to article)
Savides MC, Pohland RC, Wilkie DA, Abbott JA, Newbound GC, Freise KJ, Clark TP. The margin of safety of a single application of transdermal fentanyl solution when administered at multiples of the therapeutic dose to laboratory dogs. J. vet. Pharmacol. Therap. 35 (Suppl. 2), 35–43, 2012. (link to article)
Freise KJ, Newbound GC, Tudan C, Clark TP. Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory Beagles. J. vet. Pharmacol. Therap. 35 (Suppl. 2), 45–51, 2012. (link to article)
Linton DD, Wilson MG, Newbound GC, Freise KJ, Clark TP. The effectiveness of a long-acting transdermal fentanyl solution compared to buprenorphine for the control of postoperative pain in dogs in a randomized, multicentered clinical study. J. vet. Pharmacol. Therap. 35 (Suppl. 2), 53–64, 2012. (link to article)
Freise KJ, Linton DD, Newbound GC, Tudan C, Clark TP. Population pharmacokinetics of transdermal fentanyl solution following a single dose administered prior to soft tissue and orthopedic surgery in dogs. J. vet. Pharmacol. Therap. 35 (Suppl. 2), 65–72, 2012. (link to article)
QUICK LINKS
CONTACT US
Nexcyon Pharmaceuticals, Inc.
PO Box 259158
Madison, WI 53725
Phone: (608) 210-8060